IRWDMEDIUM SIGNALFINANCIAL10-K

Ironwood demonstrates improved operational efficiency with meaningfully reduced SG&A expenses and stronger cash generation, while expanding product labeling for LINZESS to include pediatric patients.

The substantial reduction in SG&A expenses combined with improved operating cash flow suggests management has successfully implemented cost control measures while maintaining business momentum. The expanded LINZESS labeling to include pediatric patients aged 7 and older for IBS-C represents a meaningful market expansion opportunity, while positive Phase III results for apraglutide indicate promising pipeline progress.

Comparing 2026-02-26 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

Ironwood's financial position strengthened considerably with operating cash flow growing to $127.0M and current assets expanding to $274.2M, providing enhanced liquidity. The company demonstrated disciplined expense management with SG&A costs declining substantially and R&D expenses moderately reduced, while total debt decreased to $396.3M. Despite negative stockholders' equity of -$261.8M, the improving trend in cash generation and debt reduction indicates progress toward financial stability.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
-76.1%
$142K→$34K

Capex reduced 76.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Current Assets
Balance Sheet
+50.3%
$182.4M→$274.2M

Current assets grew 50.3% — improving short-term liquidity or inventory/receivables build.

SG&A Expense
P&L
-43%
$144.3M→$82.3M

SG&A reduced 43% — improved cost efficiency or headcount reduction improving operating margins.

Accounts Receivable
Balance Sheet
-42.9%
$81.9M→$46.7M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Operating Cash Flow
Cash Flow
+22.7%
$103.5M→$127.0M

Operating cash flow grew 22.7% — strong conversion of earnings to cash, healthy business fundamentals.

R&D Expense
P&L
-14.6%
$111.4M→$95.1M

R&D spending cut 14.6% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
+13.1%
$350.9M→$396.9M

Asset base grew 13.1% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+13.1%
-$301.3M→-$261.8M

Equity base grew 13.1% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Debt
Balance Sheet
-12.8%
$454.2M→$396.3M

Debt reduced 12.8% — deleveraging strengthens balance sheet and reduces financial risk.

Inventory
Balance Sheet
-11.8%
$735K→$648K

Inventory reduced 11.8% — lean inventory management or demand outpacing supply.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-31
ADDED
Delays in the completion of clinical testing of any of our products or product candidates could result in increased costs and could delay or limit our ability to generate revenues.
Pending, threatened or future legal actions may lead to costs, reputational harm, or adverse outcomes that could materially affect our business.
FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for the treatment, in the U.S., of irritable bowel syndrome with constipation, or IBS-C, in adults and pediatric patients 7 years of age and older, chronic idiopathic constipation, or CIC, in adults, and functional constipation, or FC, in pediatric patients ages 6-17 years-old.
LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China.
Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
+7 more — sign up free →
REMOVED
Our failure to successfully develop and commercialize additional product candidates or approved products would impair our ability to grow and/or adversely affect our business.
If we are unable to execute on our strategy to in-license or acquire externally developed products or product candidates, or engage in other transactions with value creation potential, our business and prospects would be materially adversely affected.
We have identified material weaknesses in our internal control over financial reporting.
If we are not able to remediate these material weaknesses, it could have an adverse effect on our business and financial results, and our ability to meet our reporting obligations could be negatively affected.
FDA, in a class of GI medicines called guanylate cyclase type C agonists, or GC-C agonists, and is indicated for adult men and women suffering from irritable bowel syndrome with constipation, or IBS-C, or chronic idiopathic constipation, or CIC, and for pediatric patients ages 6-17 years-old suffering from functional constipation, or FC.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →